Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemically targeting the PI3K family.

Z A Knight1, K M Shokat

  • 1Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.

Biochemical Society Transactions
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Oncogene·2013
Same author

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

Leukemia·2008
Same author

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Proceedings of the National Academy of Sciences of the United States of America·2004
Same author

Phage-display evolution of tyrosine kinases with altered nucleotide specificity.

Biopolymers·2002
Same author

Recent advances in chemical approaches to the study of biological systems.

Annual review of cell and developmental biology·2001
Same author

Chemical inhibition of the Pho85 cyclin-dependent kinase reveals a role in the environmental stress response.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Phosphoinositide 3-kinase (PI3K) pathway activation drives cancer. Researchers are developing potent and selective PI3K inhibitors, highlighting recent progress and remaining challenges in targeting this crucial cancer pathway.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Phosphoinositide 3-kinase (PI3K) is integral to cellular functions including growth, metabolism, and survival.
  • Aberrant PI3K pathway signaling is frequently observed in various human cancers.
  • Targeting the PI3K pathway offers a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To review recent advancements in the development of PI3K inhibitors.
  • To discuss the challenges associated with achieving potent and selective inhibition of PI3K isoforms.
  • To provide an overview of the current landscape of PI3K-targeted cancer therapy.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of preclinical and clinical studies on PI3K inhibitors.

Related Experiment Videos

  • Synthesis of data on inhibitor efficacy, selectivity, and challenges.

    • Main Results:

    • Significant progress has been made in identifying novel PI3K inhibitors with improved selectivity.
    • Several PI3K inhibitors have demonstrated promising preclinical and early clinical activity.
    • Challenges remain in overcoming resistance mechanisms and achieving isoform-specific targeting.

    Conclusions:

    • The development of PI3K inhibitors represents a dynamic area of cancer research.
    • Targeting the PI3K pathway holds significant therapeutic potential for a range of cancers.
    • Continued research is essential to address the remaining challenges and optimize PI3K-targeted therapies.